NAD+

Dosing from the Literature

Published for longevity: oral NR and NMN doses from small randomized trials; IV NAD+ only in one pilot study and one clinic's records. Not published: a randomized trial of IV NAD+ for longevity.

NR and NMN are sold as oral supplements; NAD+ for IV and under-the-skin use is compounded by pharmacies and given at clinics or at home. The last column of each row names where its figures come from.

What It Is

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a ubiquitous coenzyme required for hundreds of enzyme reactions across all living cells. It is the electron acceptor in mitochondrial oxidative phosphorylation and the substrate for a family of NAD+-consuming enzymes — sirtuins (SIRT1–7), poly-ADP-ribose polymerases (PARPs), and CD38/CD157 — that control DNA repair, chromatin remodeling, circadian rhythm, and energy metabolism. Unlike most compounds in the Kalios database, NAD+ is not a drug or a peptide; it is an endogenous biochemical essential to life. The "anti-aging" interest in NAD+ comes from the consistent observation that intracellular NAD+ concentrations decline with age — in humans, about 10–30% lower in the older brain, liver and spinal fluid measured (Yoshino et al., 2018) — and that the decline tracks with dysfunction of the NAD+-consuming enzyme families.

The modern NAD+ era began with the work of David Sinclair (Harvard), Shin-ichiro Imai (Washington University), Charles Brenner (City of Hope), and their collaborators in the 2000s–2010s establishing that (a) sirtuins are NAD+-dependent deacetylases regulating aging-associated pathways, (b) NAD+ falls during aging, (c) administering NAD+ precursors in mice restores youthful NAD+ levels and reverses several aging phenotypes (muscle, metabolic, neurological), and (d) intermediate supply of precursor is rate-limiting rather than nicotinamide availability per se. This framework made NAD+ one of the most commercially active targets in the longevity space.

Clinically, "NAD+ therapy" in the wellness and anti-aging context refers to one of three modalities: (1) direct intravenous NAD+ infusion (user reports describe 250–1,000 mg per session; the pilot study gave 750 mg over 6 hours, Grant et al., 2019), (2) oral NAD+ precursors — nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) — taken daily, or (3) subcutaneous or nasal NAD+ formulations from compounding pharmacies. Of these, oral NR and NMN have the deepest human RCT evidence base (multiple randomized placebo-controlled trials with NAD+ biomarker elevation and some functional endpoints). IV NAD+ has a pilot pharmacokinetic study and a substantial experiential-evidence base in addiction medicine and anti-aging clinics but remains outside FDA-approved use. Oral niacin (nicotinic acid) and nicotinamide (NAM) are approved vitamins and also raise NAD+, though with different downstream profiles.

In the Kalios context, NAD+ sits in an unusual position — it is the most researched target in the longevity ecosystem but also the most contested, because several prominent preclinical findings have failed to replicate cleanly in human RCTs, and because commercial marketing has frequently run ahead of evidence. This profile stays honest about what is and is not established.

Mechanism of Action

NAD+ and its phosphorylated relatives take part in more than 400 enzyme reactions (Grant et al., 2019; PMID 31572171). It acts both as a redox cofactor (electron carrier) and as a substrate for enzymes that consume it (Verdin, 2015; PMID 26785480).

• Redox coenzyme (NAD+/NADH) — NAD+ is a cofactor in glycolysis, fatty acid β-oxidation and the TCA cycle, where it is reduced to NADH, and NADH supplies the electrons for making ATP by oxidative phosphorylation (Fang et al., 2017; PMID 28899755). NAD+ is essential for cell viability (Grant et al., 2019).
• Sirtuin (a class of longevity-linked enzymes tied to metabolism and stress response) cofactor (SIRT1–7) — Sirtuins are NAD+-dependent deacylases whose activation switches on programs of gene expression for metabolic efficiency, mitochondrial oxidative metabolism and DNA repair (Imai & Guarente, 2014; PMID 24786309). They work in the nucleus, the cytoplasm and mitochondria (Grant et al., 2019); SIRT3 and SIRT5 are mitochondrial (Yoshino et al., 2018). In animal studies sirtuin activity falls with age, and the review's authors see falling NAD+ as the likely reason (Imai & Guarente, 2014).
• PARP substrate (DNA repair) — In response to DNA damage, PARP1 breaks down NAD+ to build chains of ADP-ribose (Grant et al., 2019; PMID 31572171), and acute damage can deplete NAD+ suddenly (Imai & Guarente, 2014). Persistent PARP1 activation cut cellular NAD+ by more than half in DNA-repair-deficient rat neurons and human neuroblastoma cells (Fang et al., 2017), and the IV pilot's authors link falling NAD+ in aging to oxidative damage (Grant et al., 2019).
• CD38 consumption — CD38 is a cell-surface NAD+-glycohydrolase. In mice its protein, mRNA and activity rose with age and it was required for the age-related NAD+ decline; in human fat tissue its mRNA was up to 2.5 times higher in older than in younger people; and the authors note that inflammatory signals induce it in cells. It was also the main enzyme degrading NMN in mice, so the authors see it as a factor in NAD+-replacement therapy (Camacho-Pereira et al., 2016; PMID 27304511).
• Salvage pathway + NAMPT rate limitation — The salvage pathway, which recycles nicotinamide (NAM) into NAD+, is the main route of NAD+ synthesis (Fang et al., 2017; PMID 28899755), and nicotinamide phosphoribosyltransferase (NAMPT) is its rate-limiting enzyme (Imai & Guarente, 2014). There is some evidence that NAMPT levels fall with age, which the review's authors propose as one cause of the NAD+ decline (Imai & Guarente, 2014). NAMPT turns NAM into NMN, so taking NMN skips that step; NR is turned into NMN by the NRK enzymes; niacin enters by a separate route, the Preiss–Handler pathway (Fang et al., 2017).
• Circadian rhythm regulation — NAD+ is made on a daily cycle, because the clock proteins CLOCK and BMAL switch on NAMPT, and SIRT1 in turn acts on the clock's components (Imai & Guarente, 2014; PMID 24786309). In aging mice, a loss of SIRT1 function damps the brain's central clock (Imai & Guarente, 2014).
• Mitochondrial biogenesis — In worms and in mouse liver cells, raising NAD+ switched on the mitochondrial unfolded protein response through SIRT1 (sir-2.1 in worms), and in the cells it raised mitochondrial DNA, a sign of new mitochondria (Mouchiroud et al., 2013; PMID 23870130). In old mice, raising NAD+ restored muscle mitochondrial function through SIRT1, by a route that does not need PGC-1α (Gomes et al., 2013; PMID 24360282).
• Vascular function — In healthy middle-aged and older adults, NR lowered systolic blood pressure by 3.9 mmHg and tended to lower aortic stiffness, but neither change was significant after correction for multiple comparisons; the authors call for trials to test it further (Martens et al., 2018; PMID 29599478).
• Muscle insulin sensitivity (NMN) — In postmenopausal women with prediabetes, NMN 250 mg/day for 10 weeks improved insulin-stimulated glucose uptake in skeletal muscle (Yoshino 2021, PMID 33888596).
• IV pharmacokinetics — Grant 2019 (PMID 31572171) gave 8 healthy men 750 mg of NAD+ over 6 hours (3 more got saline): plasma NAD+ did not rise for the first 2 hours, was about 400% above baseline at the end of the infusion and was still raised 2 hours later, alongside small shifts in bilirubin, GGT, AST and LD. The authors describe it as the first study of what happens to infused NAD+ in people (Grant et al., 2019).

What the Research Shows

NAD+ is one of the most heavily researched molecules in biology. The following focuses on studies with direct relevance to human administration.

• Mechanistic reviews (Verdin 2015 PMID 26785480; Imai & Guarente 2014 PMID 24786309; Fang 2017) — Definitive consensus reviews establishing NAD+ decline as a central feature of aging and positioning NAD+ restoration as a therapeutic target.
• Sinclair aging mechanism (Gomes et al., Cell 2013; PMID 24360282) — Age-related NAD+ decline produces a pseudohypoxic state in aged mouse tissue; NMN administration reversed multiple mitochondrial dysfunction markers.
• Mitochondrial UPR (Mouchiroud et al., Cell 2013; PMID 23870130) — NAD+/SIRT1 axis activates the mitochondrial unfolded protein response, extending lifespan in C. elegans.
• NR safety + NAD+ elevation (Airhart et al., PLoS One 2017; PMID 29211728) — 8 healthy adults given NR 250–2,000 mg/day for 8 days. Whole blood NAD+ doubled on average; no clinically significant lab safety changes.
• NR chronic + vascular (Martens et al., Nat Commun 2018; PMID 29599478) — 24 middle-aged and older adults, 1,000 mg NR a day for 6 weeks, crossover RCT. NAD+ metabolism rose; systolic blood pressure fell by 3.9 mmHg on average and aortic stiffness trended down, neither significant after correction for multiple comparisons, with larger falls in the 13 subjects whose baseline blood pressure was above normal. One of the cleanest human NR trials.
• NMN in prediabetic women (Yoshino et al., Science 2021; PMID 33888596) — 250 mg NMN/day for 10 weeks; improved skeletal-muscle insulin sensitivity. First major Science publication for NMN in humans. Notably, bulk NAD+ in muscle was not detectably changed; the functional effect may be pathway- and tissue-specific.
• NR in older adults with mild cognitive impairment (Orr et al., 2024; PMID 37994989) — Pilot RCT in 20 older adults with MCI: NR rising to 1 g daily for 10 weeks raised blood NAD+ 2.6-fold and was well tolerated, but did not change cognition.
• IV NAD+ pharmacokinetics (Grant et al., Front Aging Neurosci 2019; PMID 31572171) — 750 mg over 6 hours in 8 healthy men, with 3 more given saline; plasma NAD+ did not rise for 2 hours, peaked at the end of the infusion and was still raised 2 hours later. GGT, LD and AST fell slightly and bilirubin rose slightly 8 hours after the infusion began.
• NR in skeletal muscle (Elhassan et al., Cell Rep 2019; PMID 31412242) — NR 1 g/day for 21 days in older men raised the muscle NAD+ metabolome (NAAD and methylated breakdown products, though not NAD+ itself) and produced transcriptomic anti-inflammatory signatures, without changing mitochondrial bioenergetics or grip strength.
• NMN arterial stiffness RCT (Katayoshi 2023, Sci Rep) — Long-term NMN randomized placebo-controlled trial showing favorable arterial-stiffness signal.
• NMN older men muscle (Igarashi 2021) — Japanese older men RCT showing NMN tolerability and preliminary functional signals in muscle.
• Dollerup NR in obesity (Dollerup 2018, Am J Clin Nutr; PMID 29992272) — 12-week NR RCT in obese men; no change in insulin sensitivity despite NAD+ elevation.
• NAM for non-melanoma skin cancer (Chen et al., ONTRAC, N Engl J Med 2015; PMID 26488693) — Phase 3 RCT of 500 mg nicotinamide BID in patients with high-risk NMSC; 23% reduction in new NMSC at 12 months.
• NAD+ and cancer caution (Palmer 2021) — NAD+-boosting strategies have theoretical pro-cancer signal via SIRT-mediated cell survival and NAD+-dependent mitochondrial function in transformed cells. Relevant for the risk-benefit calculation in users with cancer history.
• Across these trials (and the Freeberg 2022 trial protocol) — In the trials above that measured them, NR and NMN raised NAD+ or its metabolites in blood, while functional results were mixed: blood pressure, insulin sensitivity in obese men and muscle mitochondrial function did not change significantly (Martens et al., 2018; Dollerup et al., 2018; Elhassan et al., 2019), while muscle insulin sensitivity rose in women with prediabetes (Yoshino et al., 2021). Freeberg 2022 is the published protocol of a 3-month trial of NR, 500 mg twice a day, against placebo in 94 adults aged 50 or more with above-normal systolic blood pressure; it reports no results (Freeberg et al., 2022).

Human Data

Human evidence is strongest for oral precursors (NR, NMN). For IV NAD+ there are a pilot study, one clinic's records and a randomized trial in heart failure at 10 mg a day (Grant et al., 2019; Reyna et al., 2026; Yu et al., 2026); none of them tested it for longevity.

• NR RCTs — Airhart 2017 (PMID 29211728), Martens 2018 (PMID 29599478), Elhassan 2019 (PMID 31412242), Dollerup 2018 (PMID 29992272). Consistent NAD+ elevation; small functional effects.
• NMN RCTs — Yoshino 2021 Science (PMID 33888596), Katayoshi 2023 Sci Rep arterial stiffness, Igarashi 2021 Japanese older men. Tolerability established; muscle insulin-sensitivity signal in one pivotal study.
• IV NAD+ pilot (Grant 2019, PMID 31572171) — 8 healthy men given a 6-hour infusion, with 3 more given saline. Only published PK study.
• IV NAD+ real-world retrospective — One clinic's records: 6 clients given 500 mg by IV a day for 4 days (Reyna et al., 2026); no Phase 3 trial.
• Addiction medicine (historical) — NAD+ infusion protocols have been used since the 1960s in some addiction medicine clinics. Evidence is experiential; no modern Phase 3 trial.
• Mild cognitive impairment (Orr 2024, PMID 37994989) — Pilot RCT in 20 older adults with MCI: NR 1 g/day for 10 weeks raised blood NAD+ 2.6-fold and did not change cognition.
• Parkinson's (NADPARK, Brakedal 2022, Cell Metab; PMID 35235774) — Phase 1 NR RCT in early Parkinson's disease; increased brain NAD+ levels and trend toward clinical and biomarker benefit.
• ONTRAC NAM chemoprevention (Chen 2015, PMID 26488693) — Phase 3 RCT of oral nicotinamide for NMSC chemoprevention in high-risk patients.

Reconstitution & Storage

NAD+ for IV or SubQ use is compounded as a sterile solution or as powder to be mixed: in one clinic's records, nurses mixed 500 mg of powder with bacteriostatic water, as the supplier directed, and diluted it in 500 mL of saline (Reyna et al., 2026). Trials of NR and NMN have given them as capsules (Airhart et al., 2017; Katayoshi et al., 2023), with nothing to mix.

• IV infusion rate — The pilot study infused about 2 mg a minute, and none of its 8 men had an adverse event (Grant et al., 2019). In one clinic's records, clients set their own drip speed and slowed it because of symptoms; 500 mg took 97 minutes on average (Reyna et al., 2026). Slow, prolonged infusion is an anecdotal strategy that formal studies have not tested, the authors note (Reyna et al., 2026).
• Storage (IV NAD+) — Compounding labels list refrigeration at 2–8°C, and the compounding pharmacy sets the beyond-use date (BUD).
• Inspection — Compounding labels describe discarding the solution if it is cloudy, discolored or contaminated.

→ Calculator — vial-to-syringe math

Side Effects & Risks

In small, short trials, oral NR and NMN and a single IV infusion of NAD+ were well tolerated (Airhart et al., 2017; Martens et al., 2018; Grant et al., 2019; Katayoshi et al., 2023); in one clinic's records, IV infusions brought moderate to severe symptoms while they ran (Reyna et al., 2026).

• IV NAD+ infusion discomfort — In one clinic's records, all 6 clients given 500 mg by IV, at a drip speed they set themselves, reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, a raised heart rate, throat pain, congestion and chest pressure during the infusion; the symptoms stopped as soon as it ended (Reyna et al., 2026). In the pilot study, at about 2 mg a minute, no adverse events were observed (Grant et al., 2019). Slower infusion is an anecdotal strategy that has not been formally studied (Reyna et al., 2026).
• Flushing (niacin) — Nicotinic acid (niacin) causes flushing at therapeutic doses, through the GPR109A receptor on epithelial cells (Martens et al., 2018); flushing is among the most common side effects on the niacin label, which notes that tolerance develops over several weeks (niacin ER label). In one NR trial, flushing was reported once on NR and twice on placebo, and the authors concluded NR did not appear to cause it (Martens et al., 2018); in the nicotinamide trial, adverse events did not differ from placebo (Chen et al., 2015).
• GI upset (oral NMN/NR) — One person of 30 reported mild nausea on 1,000 mg of NR a day (Martens et al., 2018); no adverse events were reported on NMN at 250 mg a day (Yoshino et al., 2021; Katayoshi et al., 2023), and none raised a safety issue at up to 900 mg (Yi et al., 2023).
• Liver function changes (IV) — In the pilot study, GGT, LD and AST fell slightly and bilirubin rose slightly 8 hours after the infusion began (2 hours after it ended); the authors judged none of the changes clinically significant, and men with a history of liver or kidney failure were excluded (Grant et al., 2019). In one clinic's records, ALT and AST did not change over 30 days, while alkaline phosphatase fell, within the normal range (Reyna et al., 2026).
• Blood pressure effect (NR) — Systolic BP was 9 mmHg lower after NR than after placebo in the 13 people with elevated BP or stage 1 hypertension, an exploratory subgroup analysis from which the authors drew no statistical conclusions (Martens et al., 2018).
• Methyl-group consumption — Nicotinamide is cleared partly by methylation, which uses SAM as the methyl donor (Fang et al., 2017); on 1 g of NR a day for 21 days, these methylated products rose about five-fold in the muscle of 12 aged men (Elhassan et al., 2019). Whether high doses drain the body's methyl donors is theoretical.
• Hepatotoxicity (niacin) — The niacin extended-release label warns of severe liver toxicity, including fulminant hepatic necrosis, in people who switched from immediate-release to sustained-release niacin at the same dose, and does not recommend more than 2,000 mg a day (niacin ER label).
• Cancer caution — The concern is theoretical: NAD+ is essential to the viability of every cell (Grant et al., 2019), so raising it could support cancer cells too. No trial cited here studied NAD+ boosting in people with active cancer; in the ONTRAC trial, nicotinamide lowered the rate of new non-melanoma skin cancers by 23% in people with past skin cancers (Chen et al., 2015).
• Regulatory NMN question — FDA said in November 2022 that NMN was excluded from the dietary supplement definition because it had been authorized for investigation as a new drug first. On September 29, 2025 it reversed that view: NMN was marketed as a supplement in the U.S. as early as 2017, before that authorization, so it is not excluded (FDA response to citizen petition FDA-2023-P-0872).

What to Expect — Timeline

When the studies cited here measured changes:

• Oral NR — first days — Whole-blood NAD+ had doubled by day 9 in 8 healthy volunteers whose NR dose rose from 250 mg to 1,000 mg twice a day (Airhart et al., 2017).
• Oral NR — weeks 4–8 — With NR and pterostilbene taken daily, whole-blood NAD+ was up about 40% or 90%, by dose, at week 4 and stayed up through week 8 (Dellinger et al., 2017).
• Oral NR / NMN — weeks 6–10 — At 6 weeks, systolic blood pressure was 3.9 mmHg lower on NR and aortic stiffness trended down, neither significant after correction for multiple comparisons (Martens et al., 2018); at 10 weeks, NMN raised muscle insulin sensitivity in women with prediabetes (Yoshino et al., 2021).
• IV NAD+ — during and after infusion — In the pilot study, plasma NAD+ did not rise for the first 2 hours of a 6-hour infusion and was still raised 2 hours after it ended (Grant et al., 2019). In one clinic's records, symptoms came on during infusion and stopped as soon as it ended (Reyna et al., 2026).
• Biomarkers versus function — A rise in NAD+ metabolites does not guarantee a measured change: on NR, aged men's muscle showed more NAD+ metabolites but no change in mitochondrial bioenergetics or grip strength (Elhassan et al., 2019).

Bloodwork & Monitoring

No label or guideline sets monitoring for NAD+, NR or NMN. The studies cited here tracked safety with blood tests: liver tests around the IV infusion (Grant et al., 2019); liver, kidney and thyroid tests, glucose and blood lipids 30 days after a clinic's IV infusions (Reyna et al., 2026); and blood counts, a chemistry panel, liver enzymes, creatine kinase and uric acid on NR (Airhart et al., 2017). For niacin, the label lists liver tests before treatment, every 6 to 12 weeks in the first year and periodically after, and close glucose monitoring in people with or at risk of diabetes (niacin ER label).

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching NAD+ often also look at these:

Next Steps

References

1. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PMID: 26785480.
2. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. PMID: 24786309.
3. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. PMID: 24360282.
4. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154(2):430-441. PMID: 23870130.
5. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596.
6. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478.
7. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459. PMID: 29211728.
8. Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID: 31572171.
9. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.e6. PMID: 31412242.
10. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. PMID: 29992272.
11. Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, Kapogiannis D, Martens CR. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754. PMID: 36515353.
12. Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-1626. PMID: 26488693.
13. Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. PMID: 27304511.
14. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689.
15. Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022;34(3):396-407.e6. PMID: 35235774.
16. Freeberg KA, Craighead DH, Martens CR, You Z, Chonchol M, Seals DR. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Front Cardiovasc Med. 2022;9:881703. PMID: 35620522.
17. Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023;13(1):2786. PMID: 36797393.
18. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, Bohr VA. NAD⁺ in Aging: Molecular Mechanisms and Translational Implications. Trends Mol Med. 2017;23(10):899-916. PMID: 28899755.
19. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
20. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PMID: 36482258.
21. Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PMID: 41704678.
22. Yu X, Xu J, Cao J, Xu Q, Chen H, Yu D, Yao X, Chen K, Ma L. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs. 2026;26(1):97-106. PMID: 40954388.
23. Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017;3:17. PMID: 29184669.
24. McDermott MM, Martens CR, Domanchuk KJ, Zhang D, Peek CB, Criqui MH, Ferrucci L, Greenland P, Guralnik JM, Ho KJ, Kibbe MR, Kosmac K, Lloyd-Jones D, Peterson CA, Sufit R, Tian L, Wohlgemuth S, Zhao L, Zhu P, Leeuwenburgh C. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15(1):5046. PMID: 38871717.
25. Amneal Pharmaceuticals. Niacin extended-release tablets, for oral use: prescribing information. DailyMed set ID 6e604319-e164-4056-ab80-b78b98c519c7 (version 11, effective August 4, 2026). dailymed.nlm.nih.gov. Read October 4, 2026.

Related Research

• SS-31Cardiolipin-Targeted Mitochondrial Therapeutic
• Methylene BluePhenothiazine Dye / Mitochondrial Electron Carrier
• EpithalonPineal Tetrapeptide / Khavinson Bioregulator
• OxytocinNeurohypophyseal Nonapeptide Hormone
• Mito StackMOTS-c · NAD+ · SS-31 — mitochondrial support protocol
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.
• KlothoAging-Suppressor Protein / FGF23 Co-Receptor